Zacks Investment Research upgraded shares of POXEL (OTCMKTS:PXXLF) from a hold rating to a buy rating in a research note published on Friday. Zacks Investment Research currently has $9.00 target price on the stock.

According to Zacks, “Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company’s product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France. “

How to Become a New Pot Stock Millionaire

Shares of POXEL stock opened at $8.11 on Friday. POXEL has a 52 week low of $8.11 and a 52 week high of $8.11.

COPYRIGHT VIOLATION WARNING: “POXEL (PXXLF) Stock Rating Upgraded by Zacks Investment Research” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at

Get a free copy of the Zacks research report on POXEL (PXXLF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for POXEL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POXEL and related companies with's FREE daily email newsletter.